Viemed Healthcare, Inc. VMD
Misc Health and Biotechnology Services · data as of November 13, 2026
Viemed Healthcare, Inc. (VMD) is a healthcare company listed in the US with a market value of about $347M. In the twelve months to September 30, 2026 it had revenue of $310M and net income of $16M, a net margin of 5.0%.
Its overall Stock Analiz score is 3.4 out of 5 (good). The strongest part is future growth (5/5); the weakest is track record (2/5).
Key numbers: a P/E of 24.1, a price to free cash flow of 16.3, 5-year revenue growth of 16% a year, a 5-year average ROIC of 8%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 11% below the current price.
About Viemed Healthcare
Viemed Healthcare is listed in the US and classified in misc health and biotechnology services. Revenue went from $64M in 2018 to $270M in 2025, growth of about 22.7% a year. It was profitable in 8 of the last 8 years in our data. Its share count rose by 3% over three years (dilution for shareholders). It spends 1% of revenue on research and development.
Score: 3.4 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Checks not passed
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- ROE above 15%
- Pays a dividend
- Share count down over 3 years (buybacks)
- Dividend 3 years in a row
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $310M | $270M | $224M | $183M | $139M | $117M | $131M | $80M | $64M |
| Net income | $16M | $15M | $11M | $10M | $6M | $9M | $32M | $9M | $10M |
| Free cash flow | $21M | $12M | $1M | $19M | $5M | $3M | $22M | $6M | $16M |
| EPS (diluted) | $0.38 | $0.37 | $0.28 | $0.25 | $0.16 | $0.22 | $0.78 | $0.21 | $0.24 |
| Net margin | 5.0% | 5.5% | 5.0% | 5.6% | 4.5% | 7.8% | 24.0% | 10.6% | 14.8% |
| ROIC | — | 10.3% | 9.1% | 8.2% | 5.8% | 8.4% | 23.7% | 16.2% | 30.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $12.00, 31% above the current price; targets range from $10.00 to $14.00; the consensus rating is “Buy”; expected EPS is $0.40 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Viemed Healthcare’s P/E ratio?
About 24.1, based on the last twelve months of diluted earnings per share (forward P/E about 18.0).
Is Viemed Healthcare stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 11% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Viemed Healthcare pay a dividend?
Not currently.
Is Viemed Healthcare a good stock to buy?
We do not give buy or sell advice. Viemed Healthcare scores 3.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.